Literature DB >> 25917208

A new therapeutic association to manage relapsing experimental colitis: Doxycycline plus Saccharomyces boulardii.

José Garrido-Mesa1, Francesca Algieri1, Alba Rodriguez-Nogales1, Maria Pilar Utrilla1, Maria Elena Rodriguez-Cabezas1, Antonio Zarzuelo1, Maria Angeles Ocete1, Natividad Garrido-Mesa2, Julio Galvez3.   

Abstract

Immunomodulatory antibiotics have been proposed for the treatment of multifactorial conditions such as inflammatory bowel disease. Probiotics are able to attenuate intestinal inflammation, being considered as safe when chronically administered. The aim of the study was to evaluate the anti-inflammatory effects of doxycycline, a tetracycline with immunomodulatory properties, alone and in association with the probiotic Saccharomyces boulardii CNCMI-745. Doxycycline was assayed both in vitro (Caco-2 epithelial cells and RAW 264.7 macrophages) and in vivo, in the trinitrobenzenesulfonic acid (TNBS) model of rat colitis and the dextran sodium sulfate (DSS) model of mouse colitis. In addition, the anti-inflammatory effect of the association of doxycycline and the probiotic was evaluated in vitro and in vivo in a DSS model of reactivated colitis in mice. Doxycycline displayed immunomodulatory activity in vitro, reducing IL-8 production by intestinal epithelial cells and nitric oxide by macrophages. Doxycycline administration to TNBS-colitic rats (5, 10 and 25 mg/kg) ameliorated the intestinal inflammatory process, being its efficacy comparable to that previously showed by minocycline. Doxycycline treatment was also effective in reducing acute intestinal inflammation in the DSS model of mouse colitis. The association of doxycycline and S. boulardii helped managing colitis in a reactivated model of colitis, by reducing intestinal inflammation and accelerating the recovery and attenuating the relapse. This was evidenced by a reduced disease activity index, colonic tissue damage and expression of inflammatory mediators. This study confirms the intestinal anti-inflammatory activity of doxycycline and supports the potential use of its therapeutic association with S. boulardii for the treatment of inflammatory bowel diseases, in which doxycycline is used to induce remission and long term probiotic administration helps to prevent the relapses.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytokines; Doxycycline; Experimental colitis; Inflammatory bowel disease; Saccharomyces boulardii CNCMI-745

Mesh:

Substances:

Year:  2015        PMID: 25917208     DOI: 10.1016/j.phrs.2015.04.005

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  7 in total

1.  Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis.

Authors:  Grettel García-Collinot; Eduardo Osiris Madrigal-Santillán; Michel A Martínez-Bencomo; Rosa A Carranza-Muleiro; Luis J Jara; Olga Vera-Lastra; Daniel H Montes-Cortes; Gabriela Medina; María Pilar Cruz-Domínguez
Journal:  Dig Dis Sci       Date:  2019-09-23       Impact factor: 3.199

2.  Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal healing and resolution.

Authors:  J Garrido-Mesa; A Rodríguez-Nogales; F Algieri; T Vezza; L Hidalgo-Garcia; M Garrido-Barros; M P Utrilla; F Garcia; N Chueca; M E Rodriguez-Cabezas; N Garrido-Mesa; J Gálvez
Journal:  Br J Pharmacol       Date:  2018-10-15       Impact factor: 8.739

3.  Intestinal Anti-inflammatory Effects of Outer Membrane Vesicles from Escherichia coli Nissle 1917 in DSS-Experimental Colitis in Mice.

Authors:  María-José Fábrega; Alba Rodríguez-Nogales; José Garrido-Mesa; Francesca Algieri; Josefa Badía; Rosa Giménez; Julio Gálvez; Laura Baldomà
Journal:  Front Microbiol       Date:  2017-07-11       Impact factor: 5.640

4.  Mucosal delivery of Lactococcus lactis carrying an anti-TNF scFv expression vector ameliorates experimental colitis in mice.

Authors:  Maria José Chiabai; Juliana Franco Almeida; Mariana Gabriela Dantas de Azevedo; Suelen Soares Fernandes; Vanessa Bastos Pereira; Raffael Júnio Araújo de Castro; Márcio Sousa Jerônimo; Isabel Garcia Sousa; Leonora Maciel de Souza Vianna; Anderson Miyoshi; Anamelia Lorenzetti Bocca; Andrea Queiroz Maranhão; Marcelo Macedo Brigido
Journal:  BMC Biotechnol       Date:  2019-06-25       Impact factor: 2.563

5.  Probiotic and Functional Properties of Limosilactobacillus reuteri INIA P572.

Authors:  Patricia Diez-Echave; Izaskun Martín-Cabrejas; José Garrido-Mesa; Susana Langa; Teresa Vezza; José M Landete; Laura Hidalgo-García; Francesca Algieri; Melinda J Mayer; Arjan Narbad; Ana García-Lafuente; Margarita Medina; Alba Rodríguez-Nogales; María Elena Rodríguez-Cabezas; Julio Gálvez; Juan L Arqués
Journal:  Nutrients       Date:  2021-05-29       Impact factor: 6.706

6.  The Administration of Escherichia coli Nissle 1917 Ameliorates Development of DSS-Induced Colitis in Mice.

Authors:  Alba Rodríguez-Nogales; Francesca Algieri; José Garrido-Mesa; Teresa Vezza; Maria P Utrilla; Natalia Chueca; Jose A Fernández-Caballero; Federico García; Maria E Rodríguez-Cabezas; Julio Gálvez
Journal:  Front Pharmacol       Date:  2018-05-11       Impact factor: 5.810

Review 7.  Interventions of natural and synthetic agents in inflammatory bowel disease, modulation of nitric oxide pathways.

Authors:  Aida Kamalian; Masoud Sohrabi Asl; Mahsa Dolatshahi; Khashayar Afshari; Shiva Shamshiri; Nazanin Momeni Roudsari; Saeideh Momtaz; Roja Rahimi; Mohammad Abdollahi; Amir Hossein Abdolghaffari
Journal:  World J Gastroenterol       Date:  2020-06-28       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.